Molecular Formula | C11H13ClN2O3 |
Molar Mass | 256.69 |
Density | 1.23 |
Melting Point | 94℃ |
Boling Point | 349.0±44.0 °C(Predicted) |
Flash Point | 164.842°C |
Solubility | Chloroform (Sparingly), Methanol (Slightly) |
Vapor Presure | 0mmHg at 25°C |
Appearance | Solid |
Color | Yellow to Dark Yellow |
pKa | 11.63±0.10(Predicted) |
Storage Condition | 2-8°C |
Sensitive | Irritant |
Refractive Index | 1.533 |
MDL | MFCD00446053 |
Use | This product is for scientific research only and shall not be used for other purposes. |
Introduction | [(4-methoxyphenyl) hydrazinyl] ethyl chloroacetate is an ester derivative, which is an intermediate in the synthesis of apixaban. Apixaban is a new type of oral factor Xa inhibitor jointly developed by Bristol-Myers Squibb and Pfizer. The trade name is Erroto. It is a new type of oral anticoagulant. By inhibiting an important coagulation factor Xa, apixaban can prevent thrombin production and thrombosis. Apixaban was developed by Bristal-Myers squibb Company. It has good bioavailability and high selectivity. It was listed in China in 2013. Apixaban is safe, the possibility of drug interaction is small, and there are many ways to eliminate it, which is expected to be used in special groups suffering from liver disease or kidney function damage. |
Use | [(4-methoxyphenyl) hydrazinyl] ethyl chloroacetate is a useful research chemical. apixaban intermediate |